CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 511 enrolled
Drug / intervention
experimental anti-anxiety drugdrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Age 18 to 65 years
  • ✓Diagnosis of Generalized Anxiety Disorder per DSM-IV-TR criteria
Key exclusion· 1
  • ✕Other primary psychiatric diagnoses besides GAD

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00097708
NCT00097708Phase 3Completed
CompareCT.gov

A Double-Blind, Placebo Controlled Trial of an Experimental Medication For the Treatment of Generalized Anxiety Disorder

Jazz Pharmaceuticals·interventional·Posted Nov 30, 2004·Updated Oct 3, 2014

In Brief

A Phase 3 clinical trial evaluating experimental anti-anxiety drug for Anxiety Disorder. Completed, enrolled 511 participants across 50 sites.

Detailed Summary

The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 30, 2004
Enrollment StartNov 1, 2004
Study CompletionDec 1, 2005
TodayJul 2, 2026
Posted 21.6 years ago

Interventions

experimental anti-anxiety drugdrug